STAGE IV RENAL CELL CANCER AJCC V8

This study tests whether analyzing the DNA of a kidney tumor can help doctors pick the most effective treatment for advanced or metastatic clear cell renal cell carcinoma. About 54 adults who have not had prior systemic therapy will receive one of two standard drug combinations: …

This study tests whether adding a gut-health supplement called MO-03 to standard immunotherapy can help people with advanced clear cell kidney cancer live longer without their cancer growing. About 718 participants will receive either MO-03 or a placebo along with their usual tre…

This early-phase study tests whether adding a live bacteria product (EXL01) to standard immunotherapy drugs (nivolumab and ipilimumab) is safe and works better than the drugs alone for people with metastatic kidney cancer. About 33 adults will participate. The goal is to see if c…

This study tests whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can shrink or stabilize advanced kidney cancer in people with a rare inherited form (HLRCC) or sporadic papillary kidney cancer. About 65 adults with measurable tumors will receive the …

This study tests whether adding a fiber supplement called inulin gel to standard immunotherapy drugs (ipilimumab and nivolumab) can help control advanced kidney cancer better than immunotherapy alone. About 55 adults with kidney cancer that has spread or is locally advanced will …

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps control t…

This study tests a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with rare genitourinary cancers that have spread. The goal is to see if the combination shrinks tumors better than any single drug. About 314 adults with these rare cancers are being…

This phase 2 trial tests whether adding a lab-modified virus (VSV-IFNβ-NIS) to standard immunotherapy drugs (ipilimumab and nivolumab) can shrink tumors in people with advanced or metastatic clear cell kidney cancer. The virus is designed to kill cancer cells without harming norm…

This study looks at whether removing the kidney (nephrectomy) along with standard immunotherapy drugs helps people with kidney cancer that has spread live longer. About 364 participants will either get immunotherapy alone or immunotherapy plus surgery. The goal is to see if addin…

This early-phase study tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or a chemo-immunotherapy pair (nab-paclitaxel and atezolizumab) in people with advanced solid tumors in the abdomen or chest. The goal is to find …

This study tests a drug called ivonescimab given before surgery for high-risk kidney cancer that hasn't spread. The drug helps the immune system attack cancer and may also block blood vessel growth to tumors. About 31 people with clear cell kidney cancer will receive the drug bef…

This study tests whether adding precise, high-dose radiation to standard immunotherapy can better control advanced kidney cancer that has spread and cannot be surgically removed. About 240 participants will receive either immunotherapy alone or immunotherapy plus radiation to the…

This study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it in a clinic. It aims to reduce the time, cost, and stress of traveling for treatment. About 50 adults with various advanced cancers will try both settings and report which they…

This study tests whether adding cryoablation (freezing cancer cells) to standard radiation therapy provides better pain relief for people with cancer that has spread to their bones. About 40 adults with advanced cancers like prostate, kidney, or melanoma will be enrolled. The goa…

This study looks at whether getting immunotherapy in the morning or afternoon makes it work better for people with advanced or spreading solid tumors. The body's internal clock (circadian rhythm) may affect how the immune system responds. Researchers will compare progression-free…

This study tests whether giving radiation in three smaller doses (fractionated stereotactic radiosurgery) is better than the usual single large dose for people whose cancer has spread to the brain. About 269 adults with certain cancers (like lung, breast, or melanoma) will be ran…

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…